EXACT Therapeutics AS provided an update regarding the ongoing phase I ACTIVATE study. Enrolment of patients in the study at the Royal Marsden Hospital in London has been adversely impacted through the Covid-19 pandemic period. There have been seven patients enrolled in the study with five patients’ data evaluable to date. A number of valuable and encouraging insights have been gained from this first cohort of treated patients, particularly with respect to application of ultrasound. In addition, as the organisation has expanded with appointment of experienced senior executives, focus has increased on improving quality management and internal governance processes. As a consequence, robust internal governance processes have been developed and implemented. In parallel, a protocol amendment is planned with a consequent impact on patient enrolment, which is anticipated to restart in fourth quarter 2021.